Literature DB >> 28803760

Mechanism of action of botulinum neurotoxin: Unexpected consequences.

Mark Hallett1.   

Abstract

Botulinum neurotoxin (BoNT) is a widely used therapeutic in part because its mechanism of action is much wider than initially expected. Since BoNT is taken up more avidly in active presynaptic terminals, there is some selectivity for weakening muscles involved in frequent involuntary movements. BoNT blocks gamma motoneurons as well as alpha motoneurons, hence reducing afferent spindle activity which appears to have a favorable effect. Some BoNT is retrogradely transported in the motor axons, leading at least to reduction in recurrent inhibition mediated by the Renshaw cell. There are also central nervous system changes after BoNT injections and these may be due to brain plasticity. Published by Elsevier Ltd.

Entities:  

Keywords:  Botulinum neurotoxin; Brain plasticity; Dystonia; Renshaw cell; Retrograde transport

Mesh:

Substances:

Year:  2017        PMID: 28803760      PMCID: PMC5808894          DOI: 10.1016/j.toxicon.2017.08.011

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  24 in total

Review 1.  Plasticity of the human motor cortex and recovery from stroke.

Authors:  M Hallett
Journal:  Brain Res Brain Res Rev       Date:  2001-10

Review 2.  Neurophysiology of dystonia: The role of inhibition.

Authors:  Mark Hallett
Journal:  Neurobiol Dis       Date:  2010-09-15       Impact factor: 5.996

3.  The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex.

Authors:  H Wiegand; H H Wellhöner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-07       Impact factor: 3.000

4.  Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection.

Authors:  R L Rosales; K Arimura; S Takenaga; M Osame
Journal:  Muscle Nerve       Date:  1996-04       Impact factor: 3.217

5.  Effect of muscle activity immediately after botulinum toxin injection for writer's cramp.

Authors:  R Chen; B I Karp; S R Goldstein; W Bara-Jimenez; Z Yaseen; M Hallett
Journal:  Mov Disord       Date:  1999-03       Impact factor: 10.338

6.  Mechanism of action of botulinum toxin.

Authors:  M Hallett; F X Glocker; G Deuschl
Journal:  Ann Neurol       Date:  1994-09       Impact factor: 10.422

7.  Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.

Authors:  A B Scott
Journal:  Ophthalmology       Date:  1980-10       Impact factor: 12.079

8.  Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia.

Authors:  F Gilio; A Currà; C Lorenzano; N Modugno; M Manfredi; A Berardelli
Journal:  Ann Neurol       Date:  2000-07       Impact factor: 10.422

9.  The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans.

Authors:  R Eleopra; V Tugnoli; D De Grandis
Journal:  Mov Disord       Date:  1997-01       Impact factor: 10.338

10.  Botulinum toxin changes intrafusal feedback in dystonia: a study with the tonic vibration reflex.

Authors:  Carlo Trompetto; Antonio Currà; Alessandro Buccolieri; Antonello Suppa; Giovanni Abbruzzese; Alfredo Berardelli
Journal:  Mov Disord       Date:  2006-06       Impact factor: 10.338

View more
  10 in total

1.  The Use of Botulinum Toxin in the Management of Headache Disorders.

Authors:  Hsiangkuo Yuan; Stephen D Silberstein
Journal:  Handb Exp Pharmacol       Date:  2021

Review 2.  Treatment of Movement Disorder Emergencies in Autoimmune Encephalitis in the Neurosciences ICU.

Authors:  Farwa Ali; Eelco F Wijdicks
Journal:  Neurocrit Care       Date:  2020-02       Impact factor: 3.532

Review 3.  Variability of Botulinum Toxins: Challenges and Opportunities for the Future.

Authors:  Christine Rasetti-Escargueil; Emmanuel Lemichez; Michel R Popoff
Journal:  Toxins (Basel)       Date:  2018-09-13       Impact factor: 4.546

4.  Cause or effect: Altered brain and network activity in cervical dystonia is partially normalized by botulinum toxin treatment.

Authors:  Stefan Brodoehl; Franziska Wagner; Tino Prell; Carsten Klingner; O W Witte; Albrecht Günther
Journal:  Neuroimage Clin       Date:  2019-03-26       Impact factor: 4.881

Review 5.  Central Effects of Botulinum Neurotoxin-Evidence from Human Studies.

Authors:  David Weise; Christopher M Weise; Markus Naumann
Journal:  Toxins (Basel)       Date:  2019-01-06       Impact factor: 4.546

6.  Botulinum neurotoxin treatment in jerky and tremulous functional movement disorders: a double-blind, randomised placebo-controlled trial with an open-label extension.

Authors:  Yasmine Emma Maria Dreissen; Joke M Dijk; Jeannette M Gelauff; Evelien Zoons; Daniël van Poppelen; Maria Fiorella Contarino; Rodi Zutt; Bart Post; Alexander G Munts; Johannes D Speelman; Danielle C Cath; Rob J de Haan; Johannes Htm Koelman; Marina A J Tijssen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2019-06-20       Impact factor: 10.154

7.  Two cases of linear cutaneous depressions after botulinum toxin A.

Authors:  Timothy Nyckowski; Zackary Whitney; Panagiotis Mitropoulos
Journal:  JAAD Case Rep       Date:  2022-01-19

8.  Impairment of sleep homeostasis in cervical dystonia patients.

Authors:  Serena Caverzasio; Ninfa Amato; Giacomo Chiaro; Claudio Staedler; Alain Kaelin-Lang; Salvatore Galati
Journal:  Sci Rep       Date:  2022-04-27       Impact factor: 4.996

9.  Lasting Peripheral and Central Effects of Botulinum Toxin Type A on Experimental Muscle Hypertonia in Rats.

Authors:  Petra Šoštarić; Barbara Vukić; Lea Tomašić; Ivica Matak
Journal:  Int J Mol Sci       Date:  2022-10-01       Impact factor: 6.208

Review 10.  Botulinum toxin in cancer therapy-current perspectives and limitations.

Authors:  Tomasz Grenda; Anna Grenda; Paweł Krawczyk; Krzysztof Kwiatek
Journal:  Appl Microbiol Biotechnol       Date:  2021-12-24       Impact factor: 4.813

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.